AimedBio’s $991m Boehringer Ingelheim cancer deal reaches human trials, but can BI 4060107 deliver?
AimedBio's BI 4060107 enters Phase 1 testing under a potential $991 million Boehringer Ingelheim deal. Safety and early activity remain unproven.
Pharma & Biotech